Drug intelligence / Profile preview

Proteflazid

Development stage
Unknown
Lead developer
Ecopharm
Modality
Small Molecules
Administration
Oral
01

Overview

Proteflazid is a direct-acting antiviral herbal extract developed by Ecopharm. It is derived from wild cereals *Deschampsia caespitosa L.* (tufted hair grass) and *Calamagrostis epigeios L.* (bush grass) and contains flavonoid glycosides as its active components. The drug exerts its antiviral effect by inhibiting viral DNA polymerase and thymidine kinase, which are essential for the replication of both DNA and RNA viruses. Additionally, Proteflazid induces the synthesis of endogenous alpha- and gamma-interferons to physiologically active levels, thereby enhancing the host's non-specific immune response. It is indicated for a broad spectrum of viral infections, including herpes simplex virus (types 1-5), human papillomavirus (including oncogenic strains), hepatitis B and C, HIV/AIDS, influenza, and coronavirus (COVID-19). Formulated as oral drops, it has been approved for clinical use in Ukraine and other regions for patients of all ages, including newborns.

Brand names
Proteflazid
Other names
Proteflazid Drops
02

Targets

IFNG (Interferon gamma)HSV-TK (Herpes simplex virus type 1 thymidine kinase (HSV1-TK))IFN-α (Interferon alpha-7)Herpesvirus DNA polymerase

Beyond the preview

Go deeper on Proteflazid.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Proteflazid.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call